Biocure Technology Inc. (BICTF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.97 Million CAD | -5.15% |
| 2022 | 2.08 Million USD | -36.54% |
| 2021 | 3.28 Million CAD | -8.07% |
| 2020 | 3.57 Million CAD | 1.24% |
| 2019 | 3.52 Million CAD | -2.66% |
| 2018 | 3.62 Million CAD | -6.55% |
| 2017 | 3.87 Million CAD | 269.99% |
| 2016 | 1.04 Million CAD | 1052.31% |
| 2015 | 90.96 Thousand CAD | -95.4% |
| 2014 | 1.97 Million CAD | -0.02% |
| 2013 | 1.97 Million CAD | -0.93% |
| 2012 | 1.99 Million CAD | 25.32% |
| 2011 | 1.59 Million CAD | -10.46% |
| 2010 | 1.78 Million CAD | 416.0% |
| 2009 | 345.01 Thousand CAD | 83.62% |
| 2008 | 187.89 Thousand CAD | 87.84% |
| 2007 | 100.02 Thousand CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 1.46 Million USD | -2.05% |
| 2024 Q2 | 1.46 Million USD | 0.02% |
| 2023 Q2 | 2.7 Million USD | 78.45% |
| 2023 Q1 | 1.51 Million USD | -1.22% |
| 2023 Q4 | 1.49 Million USD | -42.06% |
| 2023 Q3 | 2.57 Million USD | -5.01% |
| 2023 FY | 1.97 Million CAD | -5.15% |
| 2022 Q4 | 1.53 Million USD | 2.58% |
| 2022 FY | 2.08 Million USD | -36.54% |
| 2022 Q1 | 1.86 Million CAD | -43.09% |
| 2022 Q2 | 1.63 Million CAD | -12.29% |
| 2022 Q3 | 1.49 Million CAD | -8.57% |
| 2021 Q4 | 3.28 Million CAD | -5.94% |
| 2021 Q2 | 3.83 Million CAD | -14.4% |
| 2021 FY | 3.28 Million CAD | -8.07% |
| 2021 Q1 | 4.48 Million CAD | -1.51% |
| 2021 Q3 | 3.49 Million CAD | -9.02% |
| 2020 Q1 | 4.78 Million CAD | 4.54% |
| 2020 FY | 3.57 Million CAD | 1.24% |
| 2020 Q2 | 5.02 Million CAD | 5.02% |
| 2020 Q4 | 4.55 Million CAD | -8.37% |
| 2020 Q3 | 4.96 Million CAD | -1.14% |
| 2019 Q1 | 3.69 Million CAD | 1.81% |
| 2019 Q2 | 4.04 Million CAD | 9.49% |
| 2019 Q4 | 4.57 Million CAD | 10.95% |
| 2019 Q3 | 4.12 Million CAD | 2.06% |
| 2019 FY | 3.52 Million CAD | -2.66% |
| 2018 Q2 | 3.73 Million CAD | 13.02% |
| 2018 Q4 | 3.62 Million CAD | -6.49% |
| 2018 FY | 3.62 Million CAD | -6.55% |
| 2018 Q1 | 3.3 Million CAD | -14.84% |
| 2018 Q3 | 3.87 Million CAD | 3.83% |
| 2017 Q3 | 1.97 Million CAD | 0.21% |
| 2017 FY | 3.87 Million CAD | 269.99% |
| 2017 Q1 | - CAD | -100.0% |
| 2017 Q2 | 1.96 Million CAD | 0.0% |
| 2017 Q4 | 3.87 Million CAD | 96.57% |
| 2016 FY | 1.04 Million CAD | 1052.31% |
| 2016 Q4 | 1.04 Million CAD | -46.71% |
| 2016 Q3 | 1.96 Million CAD | -0.13% |
| 2016 Q2 | 1.96 Million CAD | 0.21% |
| 2016 Q1 | 1.96 Million CAD | -0.7% |
| 2015 FY | 90.96 Thousand CAD | -95.4% |
| 2015 Q3 | 1.97 Million CAD | -0.03% |
| 2015 Q4 | 1.97 Million CAD | 0.06% |
| 2015 Q1 | 1.97 Million CAD | 0.04% |
| 2015 Q2 | 1.97 Million CAD | 0.0% |
| 2014 Q2 | 1.98 Million CAD | 0.11% |
| 2014 Q1 | 1.97 Million CAD | -0.16% |
| 2014 Q3 | 1.97 Million CAD | -0.14% |
| 2014 Q4 | 1.97 Million CAD | -0.03% |
| 2014 FY | 1.97 Million CAD | -0.02% |
| 2013 Q3 | 1.98 Million CAD | -0.54% |
| 2013 Q4 | 1.98 Million CAD | -0.05% |
| 2013 FY | 1.97 Million CAD | -0.93% |
| 2013 Q1 | 1.99 Million CAD | 0.13% |
| 2013 Q2 | 1.99 Million CAD | -0.19% |
| 2012 FY | 1.99 Million CAD | 25.32% |
| 2012 Q2 | 1.8 Million CAD | 12.99% |
| 2012 Q4 | 1.99 Million CAD | 9.88% |
| 2012 Q3 | 1.81 Million CAD | 0.81% |
| 2012 Q1 | 1.59 Million CAD | -0.72% |
| 2011 Q3 | 1.62 Million CAD | -2.19% |
| 2011 Q1 | 1.78 Million CAD | 0.07% |
| 2011 Q2 | 1.65 Million CAD | -6.92% |
| 2011 FY | 1.59 Million CAD | -10.46% |
| 2011 Q4 | 1.6 Million CAD | -0.93% |
| 2010 Q2 | 1.43 Million CAD | 163.84% |
| 2010 FY | 1.78 Million CAD | 416.0% |
| 2010 Q4 | 1.77 Million CAD | 26.72% |
| 2010 Q1 | 543.83 Thousand CAD | 58.37% |
| 2010 Q3 | 1.4 Million CAD | -2.16% |
| 2009 Q4 | 343.39 Thousand CAD | -0.47% |
| 2009 FY | 345.01 Thousand CAD | 83.62% |
| 2009 Q2 | 146.22 Thousand CAD | -1.28% |
| 2009 Q1 | 148.12 Thousand CAD | -21.02% |
| 2009 Q3 | 345.01 Thousand CAD | 135.95% |
| 2008 Q2 | 212.72 Thousand CAD | -11.55% |
| 2008 Q1 | 240.49 Thousand CAD | 131.96% |
| 2008 Q3 | 187.89 Thousand CAD | -11.67% |
| 2008 Q4 | 187.54 Thousand CAD | -0.19% |
| 2008 FY | 187.89 Thousand CAD | 87.84% |
| 2007 Q4 | 103.68 Thousand CAD | 0.0% |
| 2007 FY | 100.02 Thousand CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ContraFect Corporation | 20.67 Million USD | 90.442% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 94.912% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 72.625% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -2488.517% |
| SQZ Biotechnologies Company | 107.18 Million USD | 98.156% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -38.016% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 81.273% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 98.482% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -2631.204% |
| Marizyme, Inc. | 22.01 Million USD | 91.022% |
| Genus plc | 1.02 Billion USD | 99.808% |
| Pharming Group N.V. | 462.85 Million USD | 99.573% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 40.343% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -296.048% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -215.221% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -417.152% |
| IMV Inc. | 31.33 Million USD | 93.692% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 52.329% |
| ONE Bio Corp. | 70.08 Million USD | 97.18% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 98.462% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -156.466% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -656.452% |
| Biomind Labs Inc. | 73.81 Thousand USD | -2577.408% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.557% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 93.415% |
| Skye Bioscience, Inc. | 11.94 Million USD | 83.448% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| Mesoblast Limited | 667.9 Million USD | 99.704% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 28.034% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -0.932% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -187.487% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 24.077% |
| GB Sciences, Inc. | 103.44 Thousand USD | -1810.671% |
| MultiCell Technologies, Inc. | 126.22 USD | -1565765.948% |
| Alpha Cognition Inc. | 2.45 Million USD | 19.401% |
| HST Global, Inc. | 1526.00 USD | -129417.431% |
| CSL Limited | 38.02 Billion USD | 99.995% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Agentix Corp. | 261.39 Thousand USD | -656.12% |
| Halberd Corporation | 10.13 Thousand USD | -19408.795% |
| Enzolytics Inc. | 361.7 Million USD | 99.454% |
| Resverlogix Corp. | 8.11 Million USD | 75.645% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -5.248% |
| argenx SE | 4.54 Billion USD | 99.956% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 95.857% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 94.382% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 77.915% |
| Bioxytran, Inc. | 137.63 Thousand USD | -1335.967% |
| Zenith Capital Corp. | 7410.00 USD | -26572.551% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -514.17% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -656.201% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -112.987% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.942% |
| Kadimastem Ltd | 2.3 Million USD | 14.22% |
| Helix BioMedix, Inc. | 3.02 Million USD | 34.665% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -36.415% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 96.25% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -45.502% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -406.303% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -110.329% |
| EV Biologics, Inc. | 431.71 Thousand USD | -357.811% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -3361.723% |
| Q BioMed Inc. | 3.51 Million USD | 43.78% |
| LadRx Corporation | 2.3 Million USD | 14.361% |
| Cell Source, Inc. | 195.17 Thousand USD | -912.669% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -311.28% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -458.92% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 92.927% |
| Itoco Inc. | 1.4 Million USD | -41.167% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -1966.17% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -100.051% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -208.984% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -1764.562% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -8575.809% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 7.37 Million USD | 73.209% |
| Ember Therapeutics, Inc. | 184.00 USD | -1074050.0% |
| NovAccess Global Inc. | 62.24 Thousand USD | -3075.1% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -1282.394% |
| BioStem Technologies, Inc. | 14.56 Million USD | 86.426% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -10953.893% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -85460.0% |
| Qrons Inc. | 420.00 USD | -470480.0% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -412.733% |
| SYBLEU INC | 330.46 Thousand USD | -498.072% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -257.972% |
| Rebus Holdings, Inc. | 5000.00 USD | -39428.72% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -458.92% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -382.738% |
| Affymax, Inc. | 7.44 Million USD | 73.446% |
| Mobile Lads Corp. | 52.00 USD | -3800738.462% |
| International Stem Cell Corporation | 5.39 Million USD | 63.331% |
| CytoDyn Inc. | 11.13 Million USD | 82.252% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 86.825% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 88.079% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -2401.818% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -128.575% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 73.707% |
| Neutra Corp. | 2851.00 USD | -69224.307% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 93.901% |
| PureTech Health plc | 693.97 Million USD | 99.715% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 75.512% |
| IXICO plc | 15.84 Million USD | 87.526% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 76.136% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 98.087% |
| CSL Limited | 38.02 Billion USD | 99.995% |
| Cellectis S.A. | 333.99 Million USD | 99.408% |